Nogo-A is a challenging target associated central nervous system (CNS) regeneration as an inhibitors of neurite outgrowth, and its neutralisation may protect or restore the damage caused by numerous CNS diseases, including multiple sclerosis. To achieve this goal, we will exploit a method of rational antibody design recently developed in our lab, which is based on the computational assembly of one or more CDRs in the antibody using fragments extracted from structural databases of known interactions between amino-acid sequences. This method has been already successfully applied to several challenging targets by UCAM. A panel of antibodies against epitopes of Nogo-A will be rationally designed. Expression, purification, functional characterisation and screening of the antibodies, including binding affinity and inhibition will be determined.